Ming-Chun Hsu

Ustekinumab in adolescent patients age 12 to 17 years with moderate-to-severe plaque psoriasis: Results of the randomized phase 3 CADMUS study

Ian Landells, Colleen Marano, Ming-Chun Hsu et al. · Journal of the American Academy of Dermatology · 2015 · 224 citations · Full text

Medicine, Clinical Sciences, Dermatology +14

Ustekinumab significantly improves symptoms of anxiety, depression, and skin-related quality of life in patients with moderate-to-severe psoriasis: Results from a randomized, double-blind, placebo-controlled phase III trial

Richard G. Langley, Steven R. Feldman, Chenglong Han et al. · Journal of the American Academy of Dermatology · 2010 · 216 citations

Medicine, Dermatology, Pharmacotherapy +12

Baseline nail disease in patients with moderate to severe psoriasis and response to treatment with infliximab during 1 year

Phoebe Rich, C.E.M. Griffiths, Kristian Reich et al. · Journal of the American Academy of Dermatology · 2007 · 165 citations

Medicine, Dermatology, Pharmacotherapy +11

Long-term safety experience of ustekinumab in patients with moderate to severe psoriasis (Part II of II): Results from analyses of infections and malignancy from pooled phase II and III clinical trials

Kenneth B. Gordon, Kim Papp, Richard G. Langley et al. · Journal of the American Academy of Dermatology · 2011 · 140 citations

Medicine, Dermatology, Immunology +15

Long-term safety experience of ustekinumab in patients with moderate-to-severe psoriasis (Part I of II): Results from analyses of general safety parameters from pooled Phase 2 and 3 clinical trials

Mark Lebwohl, Craig L. Leonardi, C.E.M. Griffiths et al. · Journal of the American Academy of Dermatology · 2011 · 107 citations

Medicine, Clinical Sciences, Dermatology +10